10-Q: Cullinan Therapeutics Expands Pipeline, Reports Higher Q2 Loss

Cullinan Therapeutics reported increased Q2 losses driven by higher R&D expenses, including a new $20 million license, while advancing its clinical pipeline with positive zipalertinib data and new autoimmune programs.

Summary

• Net loss for the three months ended June 30, 2025, increased to $70.1 million from $42.0 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, increased to $118.6 million from $79.4 million in the same period of 2024.
• Research and development (R&D) expenses rose to $61.0 million for the three months ended June 30, 2025, up from $36.3 million in 2024, primarily due to a $20.0 million upfront license fee for velinotamig.
• General and administrative (G&A) expenses increased to $14.8 million for the three months ended June 30, 2025, compared to $13.8 million in 2024.
• Cash, cash equivalents, and short-term investments totaled $265.5 million as of June 30, 2025, down from $398.9 million as of December 31, 2024.
• Long-term investments and interest receivable were $245.4 million as of June 30, 2025.
• The company expects its current cash, cash equivalents, and investments to fund operations through at least twelve months from the issuance date of the financial statements (August 7, 2025).
• Zipalertinib's pivotal Phase 2b REZILIENT1 clinical trial met its primary endpoint of overall response rate in patients with EGFR ex20ins non-small cell lung cancer (NSCLC) in January 2025.
• A global exclusive license agreement was entered into with Chongqing Genrix Biopharmaceutical Co., Ltd. for velinotamig, a BCMAxCD3 bispecific T cell engager for autoimmune diseases, involving an upfront payment and potential milestones up to $692.0 million.
• Development of CLN-619 in gynecological cancers was discontinued in May 2025 due to preliminary results not meeting internal advancement thresholds.
• Development of CLN-418 was discontinued in August 2024, and rights were returned to Harbour BioMed US Inc.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significantly increased net losses and cash burn, coupled with the discontinuation of two development programs. However, this is partially offset by positive clinical trial results for zipalertinib and the strategic acquisition of a new promising asset (velinotamig), indicating continued pipeline advancement and future potential.

Positives

• Zipalertinib's pivotal Phase 2b REZILIENT1 trial met its primary endpoint of overall response rate in EGFR ex20ins NSCLC patients, with results shared at ASCO 2025 and published in the Journal of Clinical Oncology.
• Taiho Pharmaceutical Co., Ltd. plans to submit a new drug application (NDA) for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, pending FDA discussions.
• The company acquired a global exclusive license for velinotamig, a BCMAxCD3 bispecific T cell engager for autoimmune diseases, expanding its pipeline into a new therapeutic area.
• Ongoing clinical trials for multiple product candidates, including CLN-978 (autoimmune diseases), CLN-049 (AML/MDS), CLN-619 (NSCLC, multiple myeloma), and CLN-617 (solid tumors), demonstrate active pipeline progression.
• The company maintains sufficient liquidity, with cash, cash equivalents, and investments expected to fund operations for at least the next twelve months.

Negatives

• Net loss significantly increased to $70.1 million for the three months ended June 30, 2025, from $42.0 million in the prior year period.
• Total operating expenses increased substantially to $75.8 million for the three months ended June 30, 2025, from $50.0 million in the prior year period.
• Cash and cash equivalents decreased to $72.8 million as of June 30, 2025, from $83.0 million as of December 31, 2024.
• Short-term investments decreased to $192.7 million as of June 30, 2025, from $316.0 million as of December 31, 2024.
• The company discontinued further development of CLN-619 in gynecological cancers in May 2025 due to preliminary results not meeting internal advancement thresholds.
• The CLN-418 program was discontinued in August 2024, and development and commercial rights were returned to Harbour BioMed US Inc.

Risks

• The company has a history of significant operating losses and negative cash flows, expecting this to continue for the foreseeable future, requiring additional funding.
• Uncertainties associated with pharmaceutical development, government regulation, potential commercialization, and intellectual property could impact the timing or amount of funds required.
• Reliance on third parties to conduct clinical trials and manufacture drug substance and product introduces operational and supply chain risks.
• The ability to obtain and maintain regulatory approval for product candidates, along with potential restrictions or warnings, is critical for commercial success.
• Changes in global economic conditions, including international trade policies, tariffs, and supply chain dynamics, could adversely affect business and operations.
• Competition from companies marketing therapies or developing product candidates with similar targets or indications poses a significant challenge.
• The ability to identify and advance additional product candidates through clinical development is uncertain.
• Commercialization success, if products are approved, depends on the ability to build a specialty sales force and commercial infrastructure.
• The company's ability to retain and recruit key personnel is crucial for its operations.
• Obtaining and maintaining adequate intellectual property rights is essential for protecting product candidates.
• Government and third-party payor coverage, pricing, and reimbursement policies could impact product commercial viability.
• The company will become a smaller reporting company effective December 31, 2025, which could make its common stock less attractive to investors due to reduced reporting requirements.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future as it focuses on research and development. Its current cash, cash equivalents, and investments are projected to fund operations for at least the next twelve months. Key upcoming milestones include sharing updated zipalertinib data in September and October 2025, Taiho's planned NDA submission for zipalertinib by the end of 2025, Genrix's initiation of a Phase 1 velinotamig trial by the end of 2025, and initial clinical data from CLN-978 and CLN-049 trials in Q4 2025 and H1 2026, respectively. Taiho also expects to complete enrollment for the global Phase 3 REZILIENT3 trial for zipalertinib in the first half of 2026.

Management Comments

• Our strategy is to identify high-impact targets, which we define as those that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer, and then select what we believe is the optimal therapeutic modality for those targets.
• We source innovation both internally and externally, focusing on product candidates with novel technology or differentiated mechanisms.
• We expect to continue to generate operating losses for the foreseeable future.
• Our future viability is dependent on the success of our research and development and our ability to access additional capital to fund our operations.

Industry Context

Cullinan Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on developing targeted immunology and oncology programs. The company's strategy aligns with industry trends of pursuing novel therapeutic modalities, including bispecific T-cell engagers (CLN-978, Velinotamig, CLN-049) and selective kinase inhibitors (Zipalertinib), for both cancer and autoimmune diseases. The discontinuation of programs that do not meet internal thresholds reflects a common industry practice of pipeline rationalization to focus resources on more promising assets. The co-development model with partners like Taiho and licensing agreements with companies like Genrix are also prevalent strategies for risk-sharing and expanding global reach in drug development.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were detailed in the filing for direct assessment against global benchmarks.

Corporate Governance

Legal Proceedings

• The company is not currently a party to, or aware of, any material legal proceedings.

Related Party Transactions

• Co-development agreement with Taiho Pharmaceutical Co., Ltd. for zipalertinib, sharing development costs equally and 50% of future pre-tax profits from potential U.S. sales.
• License agreement with Chongqing Genrix Biopharmaceutical Co., Ltd. for velinotamig, involving an upfront license fee of $20.0 million and potential milestone payments up to $692.0 million.

Stakeholder Impact

• Shareholders: Face increased net losses and cash burn, but also potential upside from pipeline advancements (e.g., zipalertinib NDA, new velinotamig program). Risk of dilution from future capital raises and potential stock volatility due to smaller reporting company status.
• Employees: Increased R&D personnel costs suggest growth in development teams, but program discontinuations (CLN-619 in gynecological cancers, CLN-418) may impact specific teams.
• Patients: Potential for new therapeutic options from advancing clinical programs in oncology (zipalertinib, CLN-049, CLN-619, CLN-617) and autoimmune diseases (CLN-978, velinotamig).
• Creditors: The company's significant operating losses and reliance on equity financing for liquidity may be a consideration, though current cash runway is stated as sufficient for 12 months.
• Partners (Taiho, Genrix): Continued collaboration on zipalertinib and velinotamig, with potential for milestone payments and shared profits/royalties based on program success.

Next Steps

• Share updated efficacy and safety data for zipalertinib (amivantamab-treated patients) at the IASLC 2025 World Conference on Lung Cancer in September 2025.
• Share initial data from the REZILIENT2 cohort exploring zipalertinib in patients with uncommon EGFR mutations at the IASLC 2025 World Conference on Lung Cancer in September 2025.
• Share initial data from the REZILIENT2 cohort exploring zipalertinib in patients with active brain metastases at the European Society for Medical Oncology Congress 2025 in October 2025.
• Genrix plans to initiate a Phase 1 clinical trial for velinotamig in China by the end of 2025.
• Taiho Pharmaceutical Co., Ltd. plans to submit a new drug application (NDA) for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025, pending discussions with the U.S. Food and Drug Administration.
• Share initial safety data and B cell depletion data from Part A of the CLN-978 Phase 1 clinical trial in patients with systemic lupus erythematosus (SLE) in the fourth quarter of 2025.
• Share clinical data from the CLN-049 Phase 1 clinical trial in the fourth quarter of 2025.
• Taiho expects to complete enrollment of the global Phase 3 REZILIENT3 clinical trial for zipalertinib in the first half of 2026.
• Share initial clinical data from the CLN-978 Phase 1 clinical trial in patients with active, difficult-to-treat rheumatoid arthritis (RA) during the first half of 2026.
• Evaluate the impact of the U.S. budget reconciliation bill H.R. 1 (enacted July 4, 2025) on U.S. income tax laws.

Key Dates

Recommendation

The company is in a critical, high-burn R&D phase, which is typical for clinical-stage biopharmaceutical companies. While the significant increase in net loss and cash burn is a concern, it is largely attributable to strategic investments, including a substantial upfront payment for the promising velinotamig program and increased clinical trial activities. The positive Phase 2b data for zipalertinib and the planned NDA submission are significant catalysts. However, the discontinuation of two programs highlights the inherent risks in drug development. The stated liquidity provides a runway for the next 12 months, but future capital raises are anticipated. Given the balance of high operational costs and pipeline risks against the potential for future value creation from advancing clinical assets, a 'hold' recommendation is appropriate for investors monitoring the company's progress.

Keywords

Biopharmaceutical, Oncology, Autoimmune, Clinical-stage, Drug Development, SEC Filing, 10-Q, Zipalertinib, Velinotamig, CLN-978, CLN-049, CLN-619, CLN-617, NSCLC, AML, SLE, RA, SjD, EGFR, BCMAxCD3, FLT3xCD3